TITLE: METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER
INVENTORS NAME: Kevin M. Slawin et al.
SERIAL NO.: 10/071,861

1/11

TGF-B1	3 YR.	5 YR.	
≤ 4.9 ng/mL	95.1 ± 5.4%	93.4 ± 6.3%	LOG RANK TEST
> 4.9 ng/mL	85.8 ± 9.1%	74.8 ± 12.1%	P = .0105

FIG. 1

FIG. 2

TITLE: METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER
INVENTORS NAME: Kevin M. Slawin et al.
SERIAL NO.: 10/071,861

2/11

IGFBP-3	3 YR. ± SE	5 YR. ± SE
3239 ng/mL	84.7 ± 4.7%	78.7 ± 5.5%
> 3239 ng/mL	96.7 ± 2.3%	90.5 ± 4.1%

LOG RANK TEST
P = .0587

FIG. 3

| IGFBP-2	3 YR. ± SE	5 YR. ± SE
≤ 437.4 ng/mL	88.2 ± 4.2%	76.9 ± 5.7%
> 437.4 ng/mL	93.2 ± 3.3%	93.2 ± 3.3%

LOG RANK TEST
P = .0310

FIG. 4

TITLE. METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER
INVENTORS NAME: Kevin M. Slawin et al.
SERIAL NO.: 10/071,861

3/11

FIG. 5A

FIG. 5B

FIG. 5C

TITLE· METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER
INVENTORS NAME: Kevin M. Slawin et al.
SERIAL NO.: 10/071,861

4/11

IL-6 ≤ 1.9 ng/mL (MEDIAN)

IL-6 > 1.9 ng/mL (MEDIAN)

LOG RANK TEST
P = .0080

PSA PROGRESSION-FREE PROBABILITY

MONTHS AFTER RADICAL PROSTATECTOMY

FIG. 6A

IL-6 ≤ 1.99 pg/mL (MEDIAN)

IL-6 > 1.99 pg/mL (MEDIAN)

LOG RANK TEST
P = .0093

PROGRESSION-FREE PROBABILITY

MONTHS AFTER SURGERY

**FIG. 6B**

TITLE: METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER
INVENTORS NAME: Kevin M. Slawin et al.
SERIAL NO.: 10/071,861

5/11

FIG. 7

TITLE: METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER
INVENTORS NAME: Kevin M. Slawin et al.
SERIAL NO.: 10/071,861

6/11

FIG. 8

TITLE: METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER
INVENTORS NAME: Kevin M. Slawin et al.
SERIAL NO.: 10/071,861

7/11

FIG. 9

TITLE   METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER
INVENTORS NAME: Kevin M. Slawin et al.
SERIAL NO.:   10/071,861

8/11

FIG. 10

FIG. 11

TITLE   METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER
INVENTORS NAME: Kevin M. Slawin et al.
SERIAL NO.:   10/071,861

10/11

PREOPERATIVE PREDICTION OF PSA-PROGRESSION
FREE SURVIVAL IN 468 PROSTATECTOMY PATIENTS

MULTIVARIATE COX PROPORTIONAL HAZARDS ANALYSES

FACTOR	P-VALUE	HAZARDS RATIO	95% CI
PREOP PSA	0.005	1.761	1.181-2.625
BX GLEASON SUM	<0.001	2.896	1.630-5.145
CLINICAL STAGE	0.879	1.039	0.633-1.707
PREOP TGF-β1	<0.001	1.170	1.078-1.270
PREOP IL-6	0.077	1.038	0.996-1.082
PREOP IL-6 sR	0.038	1.215	1.011-1.461

FIG. 12

TITLE: METHOD TO DETERMINE PROGNOSIS AFTER THERAPY FOR PROSTATE CANCER
INVENTORS NAME: Kevin M. Slawin et al.
SERIAL NO.: 10/071,861

11/11

COMPARISON OF PREDICTIVE VALUE OF PRE-OP VERSUS POST-OP
LEVELS FOR PSA-PROGRESSION FREE SURVIVAL IN 468 PROSTATECTOMY PATIENTS

MULTIVARIATE COX PROPORTIONAL HAZARDS ANALYSES
(ALL MODELS INCLUDE PREOP PSA, ECE, GLEASON, SVI, EM)

FACTOR	P-VALUE	HAZARDS RATIO	95% CI
PREOP TGF-β_1	0.400	1.074	0.909-1.269
POSTOP TGF-β_1	0.001	1.285	1.112-1.486
PREOP IL-6	0.042	1.249	1.008-1.546
POSTOP IL-6	0.297	1.132	0.897-1.429
PREOP IL-6 sR	0.020	1.174	1.011-1.241
POSTOP IL-6 sR	0.224	0.966	0.915-1.021

FIG. 13